<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003564</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-050</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-97050</secondary_id>
    <secondary_id>NCI-T97-0078</secondary_id>
    <secondary_id>CDR0000066630</secondary_id>
    <nct_id>NCT00003564</nct_id>
  </id_info>
  <brief_title>Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas</brief_title>
  <official_title>Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
      yet known whether giving procarbazine alone or with isotretinoin is more effective for
      recurrent primary malignant glioma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of procarbazine alone or
      with isotretinoin in treating patients with recurrent primary malignant gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether the combination of isotretinoin and procarbazine can improve
      time to progression and survival compared to procarbazine alone in patients with recurrent
      malignant gliomas. II. Document the toxicity of these two regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive
      procarbazine alone or in combination with isotretinoin. Arm I: Patients receive oral
      procarbazine once daily on days 1-14 every 28 days. Oral isotretinoin is administered every
      12 hours on days 15-28 every 28 days. Patient receive 6 courses of combined therapy, then
      continue with oral isotretinoin alone on days 15-28 of each 28 day course, until disease
      progression or unacceptable toxicity. Arm II: Patients receive procarbazine by mouth once
      daily on days 1-14 followed by 2 weeks of rest. Patients receive a total of 6 courses of
      treatment in the absence of disease progression and unacceptable toxicity. Patients are
      followed until death.

      PROJECTED ACCRUAL: This study will accrue a total of 194 patients (97 per treatment group).
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn.
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression for Procarbazine alone or with Isotretinoin</measure>
    <time_frame>Six 28-day cycles</time_frame>
    <description>Effectiveness of procarbazine alone or with isotretinoin in treating patients with recurrent primary malignant gliomas measuring time to disease progression (in days).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Arm I (Procarbazine + Isotretinoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Procarbazine Alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.</description>
    <arm_group_label>Arm I (Procarbazine + Isotretinoin)</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>13-cis-retinoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine Hydrochloride</intervention_name>
    <description>Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.
Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.</description>
    <arm_group_label>Arm I (Procarbazine + Isotretinoin)</arm_group_label>
    <arm_group_label>Arm II (Procarbazine Alone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven primary malignant gliomas including the
        following: Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic
        oligodendroglioma Anaplastic infiltrating glioma Mixed malignant gliomas Must show evidence
        of tumor recurrence or progression on at least 2 serial enhanced MRI scans Must have
        measurably enhancing residual disease on MRI or CT scan of brain

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 60-100% Life
        expectancy: Greater than 8 weeks Hematopoietic: Absolute granulocyte count at least
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGPT less than 2 times institutional
        normal Alkaline phosphatase less than 2 times institutional normal Bilirubin less than 1.5
        mg/dL Renal: BUN less than 1.5 times institutional normal OR Creatinine less than 1.5 times
        institutional normal Other: No active infection Not pregnant or nursing Fertile patients
        must use effective contraception 1 month before, during, and 1 month after study No other
        disease that will obscure toxicity or alter drug metabolism No other concurrent medical
        illness

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        procarbazine No prior isotretinoin At least 4 weeks since prior chemotherapy (6 weeks for
        nitrosoureas) and recovered Endocrine therapy: Not specified Radiotherapy: Prior
        radiotherapy allowed Surgery: Not specified Other: No concurrent tetracyclines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt A. Jaeckle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

